Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
View/ Open
Date
2011-01Author
Baeten, JM
Lingappa, J
Beck, I
Frenkel, LM
Pepper, G
Wald, A
Fife, KH
Were, E
Mugo, N
Sanchez, J
Essex, M
Makhema, J
Kiarie, J
Farquhar, C
Corey, L
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.
URI
http://www.ncbi.nlm.nih.gov/pubmed/21148504http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/32282
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024584/
Citation
J Infect Dis. 2011 Jan 1;203(1):117-21.Publisher
Univesity of Nairobi Department of Medicine
Collections
- Faculty of Health Sciences (FHS) [10387]